Santacruz Silver Mining Ltd. (SCZ) Q3 Output: 1.50Moz Ag, 22,080t Zn

Santacruz Silver Mining Ltd. reported Q3 2026 production of 1.50M oz silver and 22,080t zinc. Silver from mining operations increased 2% QoQ to 1.19M oz, while Bolivar silver output grew 19% QoQ to 408,087 oz. A new 500 tpd mill for San Lucas is expected to start in Q4 2026, according to the company.

Original reporting
Published Oct 21, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Santacruz Silver Mining Ltd. (SCZ) Q3 Output: 1.50Moz Ag, 22,080t Zn — source image
Decision brief

The 30-second read

Med
01

Why it matters

QoQ improvements at Bolivar and the scheduled 500 tpd mill start in Q4 can revise near-term production expectations, which may influence sentiment toward the stock even without financial results.

02

Market read

A company-specific production print with a dated capacity catalyst, useful for traders tracking operational momentum and Q4 ramp risk.

03

What to watch

Traders may discount the update if the article omits cash costs, realized prices, capex timing, or any risk to the Q4 mill commissioning schedule.

Relevance 6/10Novelty 5/10Timing: Q3 production update with Q4 mill ramp timing.

Background

The piece summarizes Santacruz Silver’s Q3 2026 operating production and highlights a planned capacity addition at San Lucas.

Market effects

Adds incremental signal on silver and base-metal supply from a specific producer, but without broader sector guidance impact.

Limited, as the update is company-specific to its operations rather than a regional policy or macro shock.

Low, since it is not a market-wide supply disruption or major producer-level surprise.

Counterpoint

Production growth may not translate into earnings if costs, grades, or recoveries deteriorate, and the mill ramp is only expected to start in Q4.

Key entities

  • Santacruz Silver Mining Ltd.

    Reported Q3 2026 silver and zinc production and flagged a new 500 tpd mill expected to start in Q4 2026.

  • Bolivar

    Reported 19% QoQ silver output growth to 408,087 oz in Q3 2026.

  • San Lucas

    New 500 tpd mill expected to start in Q4 2026.

Related articles

$SCZMMed

Arturo Préstamo - Santacruz Silver

Santacruz Silver Mining's CEO, Arturo Préstamo, discusses the company's growing silver production, including a new 500-tonne-per-day mill at San Lucas, a $120 million treasury, and plans to produce 2.5-3 million silver-equivalent ounces annually from Soracaya. He also shares his outlook for silver prices.

$TSLAMed

Tesla Robotaxi app update now tells riders if Cybercab is the better choice

Tesla updated its Robotaxi app to show estimated arrival times and availability for Cybercab and Model Y, aiding rider decisions. Cybercab fleet grew to 573 in Texas, with plans to expand to Dallas. Elon Musk announced Cybertruck production will end by mid-2027 to prioritize Cybercab production. SpaceX targets November 13 for Starship Flight 15, aiming to catch the ship with the launch tower.

$PEGAHighAI 9/10

Pegasystems Gets Army Software Contract Capped at $419 Million

The U.S. Army awarded Pegasystems a software contract with a maximum value of $419 million. The agreement, lasting up to 10 years, covers subscriptions, cloud hosting, and professional services for authorized military organizations. Pegasystems was named the sole responsible source by the Army, citing its platform's unique features. The company announced the award on November 4.

$NVSLow

Novartis Abandons Heart Drug After Surprising Failure in Key Study

Novartis AG is halting development of pelacarsen, an experimental heart drug, after a key study showed no benefit in preventing heart attacks or cardiovascular deaths. The drug, which targets Lp(a), a cholesterol-carrying particle, failed to reduce heart attacks or strokes despite lowering Lp(a) levels. Novartis will continue one trial for a heart valve disease. The company has another experimental drug, DII235, in midstage testing.

$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.